Credits: Canva
A new study published in eLife has shed light on why dopamine-producing neurons, the brain cells crucial for motor control, die off in Parkinson’s disease. Researchers from the Gladstone Institute for Neurological Disease in the US found that these neurons may essentially be burning themselves out due to overactivity, potentially triggering or accelerating the condition.
Parkinson’s disease is marked by the progressive death of dopamine-producing neurons in the substantia nigra, the part of the brain that controls movement. Building on earlier research in animal models, the Gladstone team explored whether the surviving neurons overcompensate for lost cells by becoming hyperactive, ultimately causing damage to themselves.
To test this theory, scientists used genetically modified mice and stimulated their dopamine neurons with drugs for several days. The result: the neurons gradually degenerated and died, particularly in the substantia nigra, mirroring what happens in human Parkinson’s patients.
“An overarching question in the Parkinson’s research field has been why the cells that are most vulnerable to the disease die,” says neuroscientist Ken Nakamura from the Gladstone Institute. “Answering that question could help us understand why the disease occurs and point toward new ways to treat it.”
The study went a step further by examining changes inside these overworked neurons. Researchers found alterations in calcium levels and shifts in the expression of genes involved in dopamine metabolism and calcium regulation. These findings were mirrored in brain samples from people with early-stage Parkinson’s disease, suggesting that the mechanism seen in mice is relevant to humans.
“In response to chronic activation, we think the neurons may try to avoid excessive dopamine, which can be toxic, by decreasing the amount of dopamine they produce,” explains neuroscientist Katerina Rademacher, lead author of the study. “Over time, the neurons die, eventually leading to insufficient dopamine levels in the brain areas that support movement.”
The research suggests a troubling cycle: as some neurons die, the remaining ones become even more active to compensate, which may in turn accelerate their demise. This process is similar to lightbulbs burning too brightly and eventually blowing out.
Scientists have long debated why these vulnerable cells die, with previous theories focusing on faulty mitochondria, toxic protein clumps, and genetic mutations. This new study adds another potential cause to the list, overactivity itself.
If confirmed in further studies, this discovery could open the door to new therapies. Adjusting the firing patterns of dopamine neurons with medication or deep brain stimulation might help prevent them from overworking and prolong their survival.
“It raises the exciting possibility that adjusting the activity patterns of vulnerable neurons could help protect them and slow disease progression,” Nakamura notes.
The findings represent a step forward in understanding Parkinson’s disease, offering fresh clues for researchers seeking ways to halt or slow its devastating impact.
Credits: Wikimedia Commons, Instagram
James Van Der Beek, known best for Dawson's Creek, in a sit-down TV interview with Today, opened up about his cancer diagnosis. However, in this interview, he clarified that his weight loss was not cancer related. He shared that his family got a standing ovation during September's Dawson's Creek reunion, but he had to miss the event because he was "hit with some stomach bugs". However, he was able to join the event via Zoom call.
He clarified while he was diagnosed with stage 3 colorectal cancer last year, his weight loss was not cancer related, but due to a stomach virus. "I feel much, much better than I did a couple months ago," he said.
“I’d lost so much weight because of the stomach virus, yeah. No, it was not cancer related. Although with cancer everything’s like, ‘Why don’t we super-size that stomach virus?'” he said.
While there are no confirmed reports on what the stomach virus was, stomach flu caused by viruses like Norovirus and Rotavirus are common, however, it is the parasitic infections like Giardiasis and bacterial infections like Campylobacter that makes one lose weight.
This is a common illness caused by a parasite that could result in diarrhea and stomach cramps. This spreads through contaminated water, food, and surfaces, and from contact with someone who has it. Antibiotics can treat this.
The microscopic parasite called Giardia found especially in contaminated water could take up residence in your small intestine and feed off the nutrients there. One of the long term effects is weight loss from the chronic diarrhea and nausea.
Campylobacter is among the most common infections caused by a bacterium in humans, often as a foodborne illness. It usually happens when someone eats undercooked poultry, or drinks unpasteurized milk or contaminated water. The bacteria can make people ill with diarrhea, with nausea as a common symptom. Weight loss too is one of the clinical symptoms of this illness.
James Van Der Beek was diagnosed with stage 3 colorectal cancer after he began noticing changes in his bowel habits in the summer of 2023. At first, he brushed off the symptoms, assuming they were linked to his coffee intake. However, when the changes did not go away, he decided to consult a doctor.
A colonoscopy later confirmed the cancer diagnosis. The news came as a shock, especially since Van Der Beek had no known family history of colorectal cancer and believed he was in excellent health due to his active lifestyle and balanced diet.
Colorectal cancer develops in the colon or rectum and often begins as small, non-cancerous growths known as polyps. Over time, some of these polyps can become cancerous, interfering with digestion and the body’s ability to process waste.
It is one of the more common forms of cancer and can be difficult to detect early because symptoms may not appear right away. When they do, they often include blood in the stool, persistent changes in bowel habits, abdominal discomfort, and unexplained weight loss. According to the Mayo Clinic, early screening plays a critical role in detecting the disease when it is most treatable, and lifestyle choices can significantly influence risk and outcomes.
Credits: Canva
More than a year after Dawson’s Creek star James Van Der Beek revealed that he had been diagnosed with stage 3 colorectal cancer, the actor has shared a new update on how the illness has changed his outlook on life in unexpected ways. Speaking to host Craig Melvin on the December 19 episode of Today, James reflected on the moment he first heard the diagnosis.
“As soon as I found out, I remember thinking, ‘This might end up being the best thing that ever happened to me,’” he said. “There was this quiet voice in my head telling me that this diagnosis would push me to make changes I would never have made otherwise.”
As James Van Der Beek opens up about his health journey, many are asking: what kind of cancer was he diagnosed with?
James Van Der Beek was diagnosed with stage 3 colorectal cancer after he began noticing changes in his bowel habits in the summer of 2023. At first, he brushed off the symptoms, assuming they were linked to his coffee intake. However, when the changes did not go away, he decided to consult a doctor.
A colonoscopy later confirmed the cancer diagnosis. The news came as a shock, especially since Van Der Beek had no known family history of colorectal cancer and believed he was in excellent health due to his active lifestyle and balanced diet.
Colorectal cancer develops in the colon or rectum and often begins as small, non-cancerous growths known as polyps. Over time, some of these polyps can become cancerous, interfering with digestion and the body’s ability to process waste.
It is one of the more common forms of cancer and can be difficult to detect early because symptoms may not appear right away. When they do, they often include blood in the stool, persistent changes in bowel habits, abdominal discomfort, and unexplained weight loss. According to the Mayo Clinic, early screening plays a critical role in detecting the disease when it is most treatable, and lifestyle choices can significantly influence risk and outcomes.
As colorectal cancer often shows no symptoms in its early stages, routine screening is essential. Colonoscopies allow doctors to spot and remove precancerous polyps and detect cancer before it spreads. Early intervention has been shown to lower both the number of cases and deaths associated with the disease.
Data from the CDC highlights the importance of early detection, with survival rates varying widely by stage. While stage I colorectal cancer has a five-year survival rate of about 91 percent, that number drops sharply to around 14 percent for stage IV cases, according to the American Cancer Society. Health experts recommend beginning regular screening at age 45, or earlier for people with higher risk factors. Colonoscopy remains the most effective screening tool, as it examines the entire colon and allows for immediate removal of suspicious growths.
James Van Der Beek’s outlook following his stage 3 colorectal cancer diagnosis has been described as cautiously hopeful. His cancer was identified while still localized, a category associated with a significantly higher survival rate. According to the American Cancer Society, localized colorectal cancer has a five-year survival rate of approximately 91 percent.
James Van Der Beek has chosen not to share detailed information about the specific treatments he has received for his stage 3 colorectal cancer. In general, treatment for this stage of the disease typically involves surgery followed by chemotherapy, and in some cases, radiation therapy.
Nutritional support also plays an important role, particularly because colorectal cancer and its treatments can affect digestion. While Van Der Beek has kept the details private, he has emphasized that he is actively addressing his diagnosis and prioritizing his overall health as part of his recovery.
Credits: Canva
President Donald Trump on Thursday signed an executive order aimed at speeding up the reclassification of cannabis, a move that would allow the Food and Drug Administration to more closely examine its potential medical uses. The order states that the administration’s policy is to expand research on medical marijuana and CBD so patients and doctors have clearer, evidence-based guidance.
It also stresses the need to narrow the gap between widespread use and limited scientific understanding of possible benefits and risks, according to NBC News. Under the proposed change, cannabis would be moved to Schedule III, placing it in the same category as certain commonly prescribed pain medicines, including Tylenol with codeine.
President Donald Trump has signed an executive order that marks one of the most notable shifts in U.S. marijuana policy in decades. On December 18, he instructed federal agencies to stop treating marijuana as a Schedule I substance, a category reserved for drugs considered highly dangerous, such as heroin, LSD, and ecstasy.
The Drug Enforcement Administration defines Schedule I drugs as having no accepted medical use and a high likelihood of abuse. Trump directed that marijuana instead be placed under Schedule III, which the DEA describes as substances with recognized medical uses and a moderate to low risk of physical or psychological dependence. If implemented, this change would move marijuana away from the same legal framework as heroin and LSD and align it more closely with medicines that have established therapeutic value, such as certain acetaminophen and codeine combinations.
Schedule III drugs are regulated substances that are permitted for specific medical purposes under federal law. While their manufacture, distribution, and use are tightly controlled, they can be prescribed by licensed healthcare professionals. These rules also spell out penalties for illegal trafficking. Examples of Schedule III drugs include ketamine, anabolic steroids, and some acetaminophen-codeine medications.
Marijuana has long been listed as a Schedule I drug, a classification that assumes it is highly dangerous, addictive, and lacking medical value. Reclassifying it would shift cannabis into a category that allows lawful medical prescribing.
Marijuana has remained a Schedule I substance since the passage of the Controlled Substances Act in 1970, according to CBS News.
In the United States, Schedule III drugs are recognized for medical use and are considered less likely to be abused than Schedule I or II substances, though they may still cause moderate physical or high psychological dependence. This group includes anabolic steroids, ketamine, certain opioid combinations containing codeine or hydrocodone, such as Tylenol with Codeine, and barbiturates like pentobarbital. These medications are subject to strict rules around prescribing, dispensing, and storage to balance their medical benefits with the risk of misuse.
Once the reclassification is finalized, it is expected to make research easier by reducing funding and regulatory barriers for clinical trials. Pharmaceutical companies would also find it simpler to seek FDA approval for cannabis-based medicines. Because marijuana has been listed as Schedule I, many drug makers have avoided pursuing trials due to heavy bureaucracy and high costs. Moving it to Schedule III would lower these hurdles and allow the FDA to properly study its medical potential. This could eventually expand access to cannabis-based treatments for groups such as seniors and veterans, regardless of differing state laws.
Although the change would not legalize marijuana outright, it could bring meaningful practical effects, including clearer medical access and fewer legal uncertainties for consumers and businesses. Trump also made clear that he does not support recreational legalization. He warned that using powerful controlled substances for non-medical reasons is unsafe and said that unless a doctor recommends a drug for medical purposes, people should avoid using it, according to NBC News.
© 2024 Bennett, Coleman & Company Limited